Frazier Lifesciences Acquisition (FLAC) Annual Balance Sheets

Annual · GAAP · USD millions
Access FLAC quarterly Balance Sheets →
Examining balance sheet movements between Frazier Lifesciences Acquisition and reveals how Dec 31 2021 adjusts its asset composition and liability profile.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2021)
(Dec 31 2020)
Assets
Cash & cash equivalent1.23
Cash & Short-term Investments1.00
Prepaid Expense, Current AS0.26
Total Current Assets1.49
Other Assets, Noncurrent138.00
Total Assets139.51
Liabilities
Accounts Payable, Current AC0.17
Accrued Liabilities, Current AC0.05
Other Liabilities, Current0.00
Total Current Liabilities0.22
Total Long-term Debt0.00
Deferred Compensation Liability, Classified, Noncurrent LI4.83
Other liabilities, Noncurrent2.81
Total Liabilities7.86
Stockholders' Equity
Common Stock Value0.00
Retained Earnings / Accumulated Deficit-6.36
Other Equity-138.00
Common Stockholder's Equity-144.36
Non-controlling interests & other138.00
Total Stockholder's Equity-6.36
Liabilities & Stockholder's Equity139.51
4 historic quarters locked

Sign in to unlock the full Frazier Lifesciences Acquisition balance sheet history.

About Frazier Lifesciences Acquisition Corp Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-22-281196

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License